VerifyNow

Jump to navigation Jump to search

WikiDoc Resources for VerifyNow

Articles

Most recent articles on VerifyNow

Most cited articles on VerifyNow

Review articles on VerifyNow

Articles on VerifyNow in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on VerifyNow

Images of VerifyNow

Photos of VerifyNow

Podcasts & MP3s on VerifyNow

Videos on VerifyNow

Evidence Based Medicine

Cochrane Collaboration on VerifyNow

Bandolier on VerifyNow

TRIP on VerifyNow

Clinical Trials

Ongoing Trials on VerifyNow at Clinical Trials.gov

Trial results on VerifyNow

Clinical Trials on VerifyNow at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on VerifyNow

NICE Guidance on VerifyNow

NHS PRODIGY Guidance

FDA on VerifyNow

CDC on VerifyNow

Books

Books on VerifyNow

News

VerifyNow in the news

Be alerted to news on VerifyNow

News trends on VerifyNow

Commentary

Blogs on VerifyNow

Definitions

Definitions of VerifyNow

Patient Resources / Community

Patient resources on VerifyNow

Discussion groups on VerifyNow

Patient Handouts on VerifyNow

Directions to Hospitals Treating VerifyNow

Risk calculators and risk factors for VerifyNow

Healthcare Provider Resources

Symptoms of VerifyNow

Causes & Risk Factors for VerifyNow

Diagnostic studies for VerifyNow

Treatment of VerifyNow

Continuing Medical Education (CME)

CME Programs on VerifyNow

International

VerifyNow en Espanol

VerifyNow en Francais

Business

VerifyNow in the Marketplace

Patents on VerifyNow

Experimental / Informatics

List of terms related to VerifyNow

Associate Editors-in-Chief: Davide Capodanno, M.D. [1]


Overview

The VerifyNow system (Accumetrics, San Diego, Ca, USA; [2]) is a bedside test that allows for monitoring of the efficacy of thienopyridines, aspirin, and glycoprotein IIbIIIa inhibitors. Formerly known as the Ultegra rapid platelet function analyzer, the VerifyNow system is a turbidimetric based optical detection system which measures platelet induced aggregation as an increase in light transmittance. This system is a point-of-care and consists of an instrument, a disposable assay device and controls. The assay device contains a lyophilized preparation of human fibrinogen-coated beads, platelet agonist, preservative and buffer. Three assays are currently available, which differ according to the platelet agonist contained in the mixing chamber:

Assay device Platelet agonist Drug(s) of interest
VerifyNow GP IIb/IIIa Thombin receptor-activating peptide (TRAP) [iso-TRAP] Abciximab, eptifibatide, tirofiban
VerifyNow Aspirin Arachidonic acid Aspirin
VerifyNow P2Y12 Adenosine diphosphate Clopidogrel, prasugrel

After activation, the GP IIb/IIIa receptors on platelets will bind to the fibrinogen-coated microbeads and cross link to other microbeads resulting in a clearing of the beads and platelets within the detection well. The instrument uses light transmittance to measure the rate at which this clearing occurs. The main advantage of this test is that the patient sample is a low sample volume of 3.2% citrated whole blood, which is automatically dispensed from the blood collection tube into the assay device by the instrument, with no blood handling required by the user. Another advantage is that the instrument provides the results in minutes.


Template:WH Template:WS